|||prolonged treatment in patients with renal insufficiency.|
|||concurrent and sequential use of other drugs which may have neurotoxic and/or nephrotoxic properties. These include aminoglycosides, colistin, amphotericin B, cyclosporin, cisplatin, furosemide and ethacrynic acid. However, there is no evidence of synergistic toxicity when TARGOCID is used in combination with the above drugs.|
|||In mild renal insufficiency:|
Creatinine clearance between 40 and 60 mL per minute: the dose of TARGOCID should be halved; either by administering the initial unit dose every two days, or by administering half the initial unit dose once a day.
|||In severe renal insufficiency:|
Creatinine clearance less than 40 mL per minute and in haemodialysed patients: the dose of TARGOCID should be one third of the normal dose; either by administering the initial unit dose every third day, or by administering one third of the unit dose once a day. TARGOCID is not removed by dialysis.
|||In continuous ambulatory peritoneal dialysis:|
After a single intravenous loading dose of 400 mg, if the patient is febrile, the recommended dosage is 20 mg per litre, per bag, in the first week; 20 mg per litre in alternate bags in the second week; and 20 mg per litre in the overnight dwell bag only, in the third week.
|Lyophilised product||: Spongy, ivory-coloured, homogenous mass.|
|Solvent||: Clear, colourless, odourless liquid.|
|Reconstituted solution||: Clear, yellowish solution.|
|Lyophilised product||: Store below 25°C.|
|Reconstituted product||: May be retained for 24 hours if stored at 2 to 8°C.|
|TARGOCID FOR INJECTION||: Z/20.1.1/61|
|TARGOCID SOLVENT||: Z/34/159|
|TARGOCID FOR INJECTION||: 11 July 1994|
|TARGOCID SOLVENT||: 1 April 1992|